Purpose When information is sparse, individual parameters derived from a non-linear mixed effects model analysis can shrink to the mean. The objective of this work was to predict individual parameter shrinkage from the Bayesian information matrix (M BF ). We 1) Propose and evaluate an approximation of M BF by FirstOrder linearization (FO), 2) Explore by simulations the relationship between shrinkage and precision of estimates and 3) Evaluate prediction of shrinkage and individual parameter precision. Methods We approximated M BF using FO. From the shrinkage formula in linear mixed effects models, we derived the predicted shrinkage from M BF . Shrinkage values were generated for parameters of two pharmacokinetic models by varying the structure and the magnitude of the random effect and residual error models as well as the design. We then evaluated the approximation of M BF FO and compared it to Monte-Carlo (MC) simulations. We finally compared expected and observed shrinkage as well as the predicted and estimated Standard Errors (SE) of individual parameters. 
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INTRODUCTION
Pharmacokinetic (PK) data are usually analyzed using NonLinear Mixed Effect Models (NLMEM) originally proposed by Sheiner et al. in the 70's (1) . NLMEM describe the PK behavior of a drug in a population of subjects through estimation of PK population parameters and their between-subject variability using Maximum Likelihood (ML) approach in software such as NONMEM (2) and MONOLIX (3). Once population parameters are estimated, individual parameters can then be derived by a Bayesian approach as, for instance, the Maximum A Posteriori (MAP), by incorporating the information obtained from the population in the individual estimation. High precision in individual estimates is mandatory. Indeed, these parameters are extensively used in drug development to investigate any influence of the PK on the pharmacodynamic responses, using the sequential PKPD approach. Individual PK parameters can also be a basis for investigating any influence of physiological and demographic covariates on drug concentration and for determining whether that influence implies a dose adjustment in a subset of the population (eg: impact of cytochrome P450 genotypes on clearance), or in clinical practice to individually adapt the dose and dosing regimen via early individual parameter estimation and predictions (eg: therapeutic drug monitoring).
The informativeness of a dataset in parameter estimation is a function of the number of subjects and of the number and timing of the samples (4) . Population analysis allows the use of sparse sampling in large clinical trials, where few samples are collected in each subject. Each sampling time must be chosen carefully to be informative. To evaluate and optimize a population design, two approaches have been proposed. The first approach is based on clinical trial simulation and estimation, leading to a very time-consuming approach that limits the evaluation to a few designs and makes optimization difficult (5) . As an alternative, methods based on a mathematical derivation of the Fisher information Matrix (M F ) have been developed (6) . The inverse of the M F is used to derive the expected precision of estimation of the parameters for a given design, M F being the lower bound of the variance-covariance matrix of any unbiased estimator of the parameters (7) . Design optimization relies on the use of a criterion, such as the Doptimality criterion, which consists in minimizing the determinant of the inverse of M F over the space of possible designs, which is equivalent to reducing the expected variancecovariance matrix. This methodology was originally developed in classic non-linear regression and was first extended to NLMEM by Mentré et al. (8) and Retout et al. (9) . Its use has been facilitated by the implementation of the Individual M F (M IF ) and Population M F (M PF ) expressions in PFIM, an R function for individual and population design evaluation and optimization (10) . This approach to population design evaluation is now used in other software as an alternative to PFIM, like PopED (11), PopDes (12), POPT (13) , and has been extended to adaptive or robust optimal design in pharmacokinetic studies (14, 15) .
Although those software programs are very appealing for deriving sparse sampling design associated with good precision of population parameter estimates, they do not take into account the precision of the individual estimates by MAP. Although Merlé et al. (17) proposed an approach to predict the precision of the individual parameter estimates based on an approximation of the Bayesian information Matrix (M BF ) in NLMEM using a First Order linearization (FO), this has, to our knowledge, never been implemented in such software. For example, the current version of PFIM predicts the SE of individual estimates, but only for standard non-linear regression, assuming all variances of random effects to be null (16) . The bias in the individual estimates that can be induced by the low number of samples per subject is also not taken into account in those optimal design methodologies. Indeed, for a rich design, the a posteriori distribution of each random effect is very narrow and centered around the true value (18, 19) . However, in the case of a sparse design, with less information per subject, the a posteriori distribution is more spread out, and the mean value is close to 0. This problem of shrinkage (Sh) is well described in linear mixed-effects methodology (20) . In NLMEM, the variations in the random effects distribution and their consequences for model diagnostics have been highlighted recently by Savic et al. (21) .
The main objective of this work was to predict shrinkage associated with a design using Bayesian methodology. We first approximated M BF using FO of the model proposed by Merlé et al. in 1995 (17) . From previous work by Fedorov (20) in linear mixed effects modeling methodology, we derived a predicted shrinkage from M BF FO. Shrinkage and SE of random effects were then predicted and compared with observed shrinkage and SE estimated using simulation studies.
We used two different PK models as examples. The first is a simple one compartment PK model (22) , where different variability and uncertainty levels are considered in order to evaluate the results in various situations. The second is a two-compartment PK model with an approximated target-mediated drug disposition drawn from real clinical studies (23) and supposed to mimic the complexity of some models commonly used in drug development. Simulated data from those PK models were analyzed using both NONMEM and MONOLIX.
MATERIALS AND METHODS
Models and Notations
For a given individual, let y be the vector of n observed concentrations at n sampling times ξ={t 1 ,…,t n } and f be the known function describing the PK model. So, y can be described by y=f (θ,ξ)+ε where θ is the p-vector of individual PK parameters, θ=(θ 1 ,…,θ p ) T . ϵ is the random error, following a normal distribution with zero mean and variance Σ(θ,ξ). Σ(θ,ξ) is defined with an additive part σ inter and a proportional part σ slope with Σ(θ,ξ)= diag((σ inter +σ slope f (θ,ξ )) 2 ). Considering N individuals i following the same PK model structure, individual parameters θ i are defined as θ i =g(μ,η i ) where μ is the vector of p fixed effects and η i is the vector of individual random effects η i =(η i1 ,…,η ip ) T . Random effects η i follow a normal distribution with zero-mean and variance Ω. Here we assumed that Ω is a diagonal p×p matrix of variances of random effects Ω=diag(ω 1 2 ,…,ω p 2 ). We considered two models for g(μ, η i ): additive, where g(μ,η i )=μ+ η i , or exponential, where g μ; η i ð Þ ¼ μe η i . The vector Ψ of population parameters is composed of {μ 1 ,…,μ p ,ω 1 2 , …,ω p 2 ,σ inter ,σ slope }. As in this work we focused on individual parameter's estimation, Ψ was supposed to be known or previously estimated. By this approach we sought to avoid any bias or distribution discrepancies in parameter distribution to only validate M BF approximation.
Individual Parameter Estimation
From a vector of observed concentrations y, individual parameters can be estimated by standard individual non-linear regression. This approach does not take into account previous information. On the contrary, in NLMEM, individual parameters are usually estimated by a Bayesian approach, such as the MAP. As μ is known, estimating η is similar to estimating θ. More precisely, the MAP estimate b η of η is given by:
It can be also written, using Bayes theorem,
as p( y) is independent of η.
Bayesian Fisher Information Matrix
For individual estimation, in a non-linear model, M IF for parameters θ is:
For homoscedastic error, M IF is expressed as:
where
For Bayesian estimation of the random effects, M BF is defined by (22) :
In Eq. (5), M BF is a sum of 2 matrices respectively representing individual and prior information. As p(η) is
Also, noting the link between the first part of the equation and M IF , we have:
We used two methods to compute M BF (17) . An evaluation by Monte-Carlo simulation (M BF MC), where a large number of η i are simulated from N(0, Ω) and the expectation in Eq. (5) is computed as the empirical mean. M BF can also be evaluated using FO linearization of the model around the random effect in the expression of the likelihood. It can be shown that M BF is then approximated by:
where M is an identity matrix (I) for additive random effects, and Μ=diag(µ 1 ,…,µ p ) for exponential random effects. M BF is the expected information over all η. We can also compute the Bayesian information Matrix for a given individual (M IBF ) which depends on its random effect. Using FO, M IBF is approximated by:
where Θ is an identity matrix for additive random effects, and Θ=diag(θ 1 ,…,θ p ) for exponential random effects.
Predicted Shrinkage
Shrinkage in linear mixed effect models is well established (24) and Fedorov in 2011 (20) proposed the matrix I-W for its quantification. Assuming that the linear model is defined as y=F(ξ)θ+ε, then, for individual estimation
where (25) . In both (20) and (24), it is shown that the MAP estimate of θ can be expressed as
By setting
Then,
Equation (10) becomes
W then quantifies the balance between prior and indi-
We propose to extend this formula in non-linear mixed-effect models where W is computed from M BF as:
As Ω is diagonal, the diagonal elements of I-W are the ratio of the predicted estimated variance of the Bayesian estimation and the a priori variance. When M BF −1 is close to Ω (no information), I-W is close to I. In this case, shrinkage is expected to be high.
Simulation Study
Example 1
We used a simulated example inspired by similar methodology reported by Mentré et al. (22) . This theoretical example involved a one-compartment PK model with IV bolus administration. The two parameters are volume of distribution (V) and clearance (CL). For a given dose D, the prediction at time t j is:
with θ 1 =V and θ 2 =CL. We assumed μ V =0.2 IU, μ CL =0.5 IU and a dose D=1 IU. As this model is theoretical, we did not consider any specific units. To compute the Fisher matrices in various situations, we considered several scenarios with different types of random effects models (ie: additive or exponential), different types of residual error models (ie: additive or combined) and different values for the random effects. No correlation between parameters was assumed. All scenarios are given in Table I . Scenarios were named with two letters, the first one representing the type of random effect models and the second one the type of residual error model (ie: a for additive, e for exponential, and c for combined). The lower and upper-case letters stand for low variance (Coefficient of Variation (CV) of 20%) and high variance (50% CV) of random effect, respectively. For this example 1, we performed two simulations A and B. Simulation A evaluates the use of M BF in predicting shrinkage for each scenario, the vector Ψ of population parameters being considered as known and fixed at the true simulation value. We defined a set of five possible sampling times: {0.05, 0.15, 0.3, 0.6, 1} and D-optimal designs with 2 to 5 samples were derived considering the first (aa) scenario. These designs are described in Table II . Simulation B compares predicted versus observed shrinkages in a more realistic setting, incorporating the discrepancies due to the population parameter estimation step as often encountered in a real estimation context. This simulation B was performed for scenario ec using a combined design with 2 groups of 50 and 150 subjects each containing 5 and 2 samples per subject respectively, with sampling times similar to those in simulation 1 (Table II ). An additional investigation using this example was performed to explore the impact of M BF on design optimization and is presented in the Supplementary Materials I. We compared the optimal design obtained with M BF and M PF and computed the loss of efficiency associated with each one.
Example 2
The second example is a more complex PK model, adapted from the population pharmacokinetic model of an antiinterleukin-6 receptor antibody used as rheumatoid arthritis treatment (23) . The PK model, established using a large 
where k 10 , k 12 and k 21 are rate constants of drug exchanges between the different compartments:
; C 1 is the concentration in the central compartment:
, where CL denotes the clearance, V 1 is the volume of distribution of the central compartment, V 2 is the volume of distribution of the peripheral compartment, V m is the maximum elimination rate, K m is the Michaelis constant, and Q is the intercompartmental clearance.
The population parameter values are detailed in Table III . A combined error model and exponential random effects were used. As the FO approximation is appropriate only with small variances, for simplicity, we rounded off fixed effect values and assumed 30% CV for betweensubject variability on CL, V 1 (Table SII and Figure S1 ). Six repeated one-hour infusions every 4 weeks at the dose of 8 mg/kg were assumed. Four different designs were simulated, involving 10, 9, 4 or 2 samples per subject, at the same sampling times, with 1,800 subjects. The design with 10 samples was created by collecting 3 samples after the first dose (end of infusion, 10 and 20 days), 3 pre-doses samples before the 2nd, 3rd and 5th doses, and then 4 samples after the last dose (end of infusion, 20, 28 and 56 days after the last dose). The last sample (56 days after the last dose) was removed for the 9-samples design. Using the same sampling allocations, a peak and trough design was applied after the first dose for the 2 samples per subject design. From this last design, 2 sampling allocations after the last dose (end of dose and 56 days after the last dose) were added to create a 4 samples per subject design. Sample allocations are detailed in Table IV .
Software and Analysis
For example 1, datasets were simulated using R 2.14. NONMEM 7.0 and MONOLIX 4.0 were used to estimate individual random effects and their precision of estimation (estimated SE) given the model. We used two software programs as they are both extensively used and considered as references in drug development for population analysis using NLMEM. For simulation A, one dataset of 1,000 subjects was simulated per scenario and per design. Population parameters estimation was skipped using specific options in both software programs and only individual parameters were estimated as MAP. In NONMEM, population parameters were specified to their true values by using the option MAXEVAL = 0 (number of objective function evaluations) (26) , and individual parameters were estimated 
Random effects (CV%) ω CL 30
Residual error σ inter (μg/ml) 0.5 σ slope (%) 30 using the first order conditional estimation with interaction method (FOCEI). In MONOLIX, the number of chains and the number of iterations (K 1 and K 2 ) were specified respectively at 5 chains, 800 and 300 iterations with fixed population parameters. For simulation B, we simulated 1,000 datasets and estimated both population and individual parameters using the SAEM algorithm implemented in MONOLIX.
In a first step, using the individual random effects estimates given by NONMEM, we investigated the influence of shrinkage on individual estimates and on estimated random effects distribution. Then, in order to evaluate the expression of M BF with the FO approximation, we compared Relative Standard Errors (RSE) computed with M BF FO to M BF MC using the 1,000 simulated subjects. We also compared the quantity of information provided by the 3 considered regressions (individual with M IF , population with Ω and individual Bayesian with M BF ). Ω defined the variance of the estimation yielded by Bayesian estimation without any individual information, and is therefore an upper bound of the variance of the individual Bayesian estimation. Predicted shrinkage computed with M BF FO was compared with observed shrinkage (Sh) on random effects estimated with NONMEM and MONOLIX without population estimation, and MONOLIX with population estimation. Observed shrinkage for parameter k was defined as (21):
b η i;k being the estimated value of η, and var b η i;k À Á the empirical variance, estimated by NONMEM or MONOLIX. Note that in the case of very low shrinkage Eq. (18) can produce negative values which were set to 0. Although Savic et al. expressed shrinkage as the ratio of standard deviations, the ratio of variances, which is more usual in biostatistics, was used here. All thresholds and values extracted from Savic et al. were converted to ratio of variances in the present paper. Finally, using simulation results, we compared each estimated individual SE with the predicted SE obtained from the diagonal of M IBF −1 .
Datasets for example 2 were simulated with NONMEM 7.0, and the same options as for example 1 (simulation A) were used for estimation with NONMEM 7.0 and MONOLIX 4.0. We performed two steps similar to those in the first example: we compared predicted vs observed shrinkage and individual SE. M BF , M IF and shrinkage computations were performed with R 2.14. This methodology should be implemented in a future version of PFIM. Meanwhile, the R code used to compute M BF , SE, RSE and predicted shrinkage is given in Supplementary Materials III.
RESULTS
Example 1
Shrinkage Impact on Individual Estimates
The simulated scenarios generated observed shrinkage values that ranged from 0% to 69% for CL and from 0 to 52% for V. All the shrinkage values are given in Table V for each scenario and for each number of samples per subject for the two software programs. The highest shrinkage was obtained for 2 samples per subject with a low variance for CL and V and a combined error model. As NONMEM and MONOLOX provide similar results, and as the observations for volume are similar to those for clearance, only NONMEM results for clearance are shown and discussed in the rest of this section. Figure 1 presents individual parameter estimated with NONMEM vs simulated parameters along with observed shrinkage for each scenario and for each number of samples. This figure also shows the distribution of estimated and simulated random effects. With small shrinkage (≈7% for clearance, scenario ea with 5 samples), the estimated η distribution (in red) is close to the simulated η distribution (in black) and the simulated and estimated individual parameters are close to the identity line. With 2 samples per subject with the same scenario, the shrinkage increases to 20%. The simulated and estimated η distributions remain relatively similar, as do the simulated and estimated individual parameters. Changing the form of the random effects from exponential to additive with the same variance (20% CV) had no major effect on shrinkage or parameter estimation. Changing the residual error from additive to combined for the same scenario increased the shrinkage to 69%. For this high shrinkage, the estimated η distribution clearly shrank towards zero, and the estimated individuals parameters deviated from the simulated values. When the CV of exponential random effects was increased to 50% CV, individual random effects were very well estimated whatever the design used. Thus, shrinkage for a combined error model and 2 samples per subject decreased to 33%. . Similar values were found for low between-subject variability, and only slight differences were observed, without exceeding 5% for higher variances of random effects (scenarios Ea, Ec). Note that as expected, predicted RSE increased with decrease of information per subject. 
Evaluation of M BF FO Approximation
Optimal Design
In Supplementary Materials I, we compared the criteria from M BF and M PF for 3420 designs. We found that the optimal designs for Sh-optimality and population-optimality differed, and were {0.05, 0.75, 0.8} and {0.05, 0.35, 1}, respectively. Also, for each criterion (M BF or M PF ) there was a loss of efficiency when using the design optimal for the other criteria (see Table SI ). 
Shrinkage Prediction
SE of Random Effects
SE from M IBF −1 were computed and then compared with estimated SE of individual random effects using NONMEM and MONOLIX. The results are shown in Fig. 4 . As expected, SE decreased when the number of samples for each subject increased, for the four methods. Adding a proportional part in the residual error model led to an increase in median SE. In the same way, changing random effects from additive to exponential or increasing the value of their variance from . Similar values were observed with NONMEM and MONOLIX. Predicted SE from M IBF −1 were very close to the estimated SE for all scenarios. In the case of a combined error model, MONOLIX systematically estimated a wider distribution of the SE of volume.
Example 2
Shrinkage Prediction Figure 5 shows predicted vs observed shrinkage for each parameter of the complex model and each design. The dots were close to the identity line whatever the number of samples per subject and the PK parameter. There was slightly better agreement between the predicted shrinkage and the shrinkage computed using MONOLIX individual estimates than with the NONMEM estimates, especially for CL for the 2 designs with the smaller number of samples. In section II of the Supplementary Material we report two simulations for which real variability values of the basic model as well as intermediate ones (see Table S1 ) were used to compare predicted versus observed shrinkage. These simulations showed some discrepancies between predicted and observed shrinkage, especially for V 2 , and these discrepancies increased with variability (see Fig. S1 ). 
SE of Random Effects
DISCUSSION
We proposed a method to predict shrinkage using an approximation of M BF in NLMEM based on a FO linearization and we evaluated it for a large range of shrinkage values and from a simple linear PK model to a more complex nonlinear one. The approximated M BF was very close to the one obtained by Monte-Carlo simulations and the proposed prediction method was shown to give a very good prediction of observed shrinkage. Our investigations also highlight that shrinkage is influenced by design (eg: number of samples per subject and sample allocations), but also by the ratio between residual error and random effect variances, a small ratio resulting in high shrinkage.
To the best of our knowledge, this is the first time that shrinkage has been predicted using M BF in NLMEM. The main publications regarding Bayesian design evaluation and optimization in NLMEM were written by Merlé et al. (17) and Mentré et al. (22) in the 90's. The first paper focuses on defining and simplifying the computation of three Bayesian design criteria for several designs and PK models: the determinant of M BF , the determinant of the pre-posterior covariance matrix and the expected information provided by an experiment. These criteria indicate the relevance of computing the matrices using a linearization of the model around the mean of the prior distribution. The second paper focuses on the use of the determinant of M BF to optimize the design for Bayesian individual estimates. Several population and Bayesian designs are evaluated and compared in this study, from which the authors concluded that there is a difference between the optimal Bayesian and population designs, even if optimal Bayesian designs sometime involve the same sampling times than the optimal population design. In the present work, we confirmed that optimal Bayesian and population designs are different for a given model.
With the proposed approach in this publication, shrinkage optimization can be included in addition to optimization of the SE of the population parameters. This optimization requires the use of compound criteria and evaluation of the impact of the weight of each criterion on the design and on the population and individual parameter estimates (27) .
This work also evaluated the expression and the use of individual M BF to predict SE of the individual parameter estimates. In all investigated cases the predictions were very close to the individual SE generated by NONMEM and MONOLIX. In some cases, the ranges of the individual SE estimated by MONOLIX were found to be higher than in NONMEM. This was especially the case for the volume of distribution of the more complex PK model. This may be due to the fact that MONOLIX computes the variance of the conditional distribution without linearization.
Although the predicted and observed shrinkages were similar, we observed minor discrepancies for example 2. For 2 or 4 samples per subject, predicted shrinkages on CL and V 1 were below the observed values. This was not the case when individual parameters were estimated by MONOLIX. Considering M IBF computation of SE in this more complex model, predictions were close to the estimated results using NONMEM for all parameters except V 1 . SE distributions estimated using MONOLIX were wider than those with NONMEM, with a similar median. We hypothesized earlier in this paper that these differences stem from the different SE computation methods used in NONMEM and MONOLIX, but further investigation is warranted. In this paper, we made the assumption of a diagonal Ω matrix for the sake of simplicity. The same formula would hold for a non-diagonal matrix.
Prediction of shrinkage was evaluated for example 2, changing the variances of the random effects to smaller and more reasonable value of 30% compared with the true base model developed by Frey et al., which estimated 110% variability on V 2 . However, although the FO approximation used to compute M BF performs very well for reasonable variability, increase in variability worsened prediction, especially for very large variabilities as shown in the Supplementary Materials. This is certainly a limitation of the FO approximation, which is known to be appropriate only if the variances of the random effects are relatively small (28, 29) .
In example 1 -simulation A and example 2, population parameters were set to their true value. With this method, , red ones are SE estimated by NONMEM and green by MONOLIX. Black diagonal cross "X" is the value predicted by M BF −1 using FO approximation. we wanted to avoid any bias or distribution discrepancies in parameters distribution. Indeed, the goal of this simulation was to evaluate the prediction of shrinkage and individual SE for some given estimated individual parameters, with the smallest possible external influence such as population parameters estimation. However, to explore what could happen in a real estimation context, we also explored the deviation between predicted shrinkage computed for true simulation values and the observed shrinkage obtained after a first step in estimation of the population parameters and a second Bayesian step in estimation of the individual parameters. This exploration showed a good agreement between predictions and observations. Nevertheless, we acknowledge that the example used was rather simple with a fully informative design (combined sparse and rich elementary design with 120 and 50 subjects), and that further investigations with more complex models as often encountered in drug development associated with rather sparse designs should be performed. Lastly, Savic et al. (21) showed that high shrinkage can induce or hide a correlation between parameters and covariates. A hypothesis of no correlation could therefore be falsely accepted when this correlation does not truly exist. One perspective would be to link the shrinkage with the power of the test used to detect that covariate. That could minimize the risk of falsely detected (or not detected) influence of some covariate due to uninformative design. Future work should then focus on the impact of the precision of estimates on covariate selection and on the link between shrinkage and the power of the test for covariate selection.
CONCLUSION
We introduce a methodology based on the Fisher information Matrix to predict accurately the shrinkage associated with a given design in non-linear mixed-effect models. Bayesian evaluation will soon be implemented in PFIM to allow an easy prediction of shrinkage when planning pharmacokinetic studies. It opens up perspectives for better design and more relevant estimates of the individual pharmacokinetic parameters from population analysis.
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